Cinctive Capital Management LP Increases Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Cinctive Capital Management LP grew its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 140.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 81,320 shares of the biopharmaceutical company’s stock after purchasing an additional 47,523 shares during the period. Cinctive Capital Management LP owned approximately 0.12% of Celldex Therapeutics worth $2,055,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. EverSource Wealth Advisors LLC grew its holdings in Celldex Therapeutics by 215.7% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 878 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Celldex Therapeutics during the 4th quarter worth $81,000. KBC Group NV grew its stake in shares of Celldex Therapeutics by 79.1% during the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 1,647 shares during the period. AlphaQuest LLC grew its stake in shares of Celldex Therapeutics by 171.0% during the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 2,705 shares during the period. Finally, E Fund Management Co. Ltd. acquired a new stake in shares of Celldex Therapeutics in the fourth quarter valued at about $273,000.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on CLDX. Morgan Stanley started coverage on shares of Celldex Therapeutics in a research report on Thursday, March 20th. They set an “overweight” rating and a $46.00 target price on the stock. The Goldman Sachs Group dropped their price objective on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Friday, February 28th. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Finally, UBS Group assumed coverage on Celldex Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $44.00 price target for the company. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $54.33.

Celldex Therapeutics Stock Up 3.1 %

Shares of NASDAQ:CLDX opened at $17.38 on Thursday. The company has a market capitalization of $1.15 billion, a P/E ratio of -6.76 and a beta of 1.76. Celldex Therapeutics, Inc. has a 52-week low of $16.40 and a 52-week high of $47.00. The stock’s fifty day simple moving average is $21.49 and its 200-day simple moving average is $25.81.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.02. The firm had revenue of $1.18 million during the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. On average, sell-side analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.